Abstract
Initial clinical development of PARP inhibitor (PARPi) started for ovarian patients with germline BRCA mutation (gBRCAm) based on the mechanistic assumptions. The first large phase 3 trial, SOLO2, focused on the patient with platinum-sensitive recurrent ovarian cancer known to have gBRCAm. On the other hand, the NOVA trial tested the innovative study design. The investigators challenged to include patients with not only gBRCAm but also with non-gBRCAm, which included HRD+ (tBRCAm only and BRCAwt) and HRD-negative population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
